“Only those who invest ahead of demand while staying lean and interoperable will be able to support the next wave of complex biologics,” says Pierre Catignol, EVP and Head of Operations at Samsung Biologics.
Samsung Biologics, with its proven track record of accelerating technology transfers, meeting quality expectations, and demonstrating flexibility under pressure, offers strategic partnership opportunities during a global capacity squeeze in the biomanufacturing sector.
Read the full article in Genetic Engineering & Biotechnology News.
“Only those who invest ahead of demand while staying lean and interoperable will be able to support the next wave of complex biologics,” says Pierre Catignol, EVP and Head of Operations at Samsung Biologics.
Samsung Biologics, with its proven track record of accelerating technology transfers, meeting quality expectations, and demonstrating flexibility under pressure, offers strategic partnership opportunities during a global capacity squeeze in the biomanufacturing sector.
Read the full article in Genetic Engineering & Biotechnology News.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article